Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-03

AUTHORS

Nadja E. Schoemaker, I. E. L. M. Kuppens, Wim W. Ten Bokkel Huinink, Patricia Lefebvre, Jos H. Beijnen, Sylvie Assadourian, Ger-Jan Sanderink, Jan H. M. Schellens

ABSTRACT

A phase I study was conducted with oral irinotecan given daily for 14 days every 3 weeks in 45 patients with solid tumours to establish the maximum tolerated dose (MTD), toxicity, preliminary antitumour response and pharmacokinetics. Irinotecan was administered orally as a powder-filled capsule at doses ranging from 7.5 to 40 mg/m2 per day. Tumours were predominantly colorectal (30) together with 10 other gastrointestinal, 2 breast, 2 small cell lung and 1 ovarian. All but three patients had received prior chemotherapy. The median number of administered cycles was 3 (range 1-19). Gastrointestinal toxicities (grade 3 nausea, grade 3/4 vomiting and diarrhoea) and one incidence of grade 3 asthenia were dose limiting. There were no grade 3/4 haematological toxicities. The MTD was 30 mg/m2 per day. There were two documented partial responses, one in a patient with cancer of the small intestine and the other in a patient with colon cancer. Stable disease was seen in 16 patients (35.5%). Peak concentrations of irinotecan and metabolite SN-38 were reached within 2.0-2.4 h. The metabolic ratio of SN-38 AUC to irinotecan AUC was 0.17+/-0.10 (mean+/-SD). The dose recommended for phase II studies is 30 mg/m2 per day administered daily for 14 days every 3 weeks. More... »

PAGES

263-270

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-004-0874-2

DOI

http://dx.doi.org/10.1007/s00280-004-0874-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007848801

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15592838


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Phytogenic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Tract", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Topoisomerase I Inhibitors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schoemaker", 
        "givenName": "Nadja E.", 
        "id": "sg:person.0660632545.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660632545.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands", 
            "Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuppens", 
        "givenName": "I. E. L. M.", 
        "id": "sg:person.012165545074.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012165545074.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huinink", 
        "givenName": "Wim W. Ten Bokkel", 
        "id": "sg:person.01351666475.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351666475.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Aventis Pharma, 20, Avenue Raymond Aron, 92165, Antony cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lefebvre", 
        "givenName": "Patricia", 
        "id": "sg:person.0710100376.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710100376.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Utrecht University", 
          "id": "https://www.grid.ac/institutes/grid.5477.1", 
          "name": [
            "Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands", 
            "Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, 3584 CA, Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beijnen", 
        "givenName": "Jos H.", 
        "id": "sg:person.01167077171.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167077171.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Aventis Pharma, 20, Avenue Raymond Aron, 92165, Antony cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Assadourian", 
        "givenName": "Sylvie", 
        "id": "sg:person.01324150036.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324150036.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Utrecht University", 
          "id": "https://www.grid.ac/institutes/grid.5477.1", 
          "name": [
            "Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, 3584 CA, Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sanderink", 
        "givenName": "Ger-Jan", 
        "id": "sg:person.01016732660.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016732660.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Utrecht University", 
          "id": "https://www.grid.ac/institutes/grid.5477.1", 
          "name": [
            "Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands", 
            "Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, 3584 CA, Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schellens", 
        "givenName": "Jan H. M.", 
        "id": "sg:person.013575273137.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013575273137.17"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)02034-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006410174"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200009283431302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010303757"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)02309-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017322568"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1097-0142(19990215)85:4<786::aid-cncr5>3.0.co;2-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027733495"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-4347(98)00554-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027875779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199704000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031175331"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199704000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031175331"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)03085-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034082860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200107123450213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036903462"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(98)00353-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037007269"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00686188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043894508", 
          "https://doi.org/10.1007/bf00686188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00686188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043894508", 
          "https://doi.org/10.1007/bf00686188"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048065376", 
          "https://doi.org/10.1038/bjc.1997.491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048065376", 
          "https://doi.org/10.1038/bjc.1997.491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.2.685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074265671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.6.1897", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.3.659", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074583472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074698413", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.5.1501", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074777260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074859792", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.18.3801", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074881994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a059109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082507233"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.3.709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082882771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.1.110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083031469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.1.251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083031490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.4.1502", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083105876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.8.2910", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083129507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083312377", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083347163", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-03", 
    "datePublishedReg": "2005-03-01", 
    "description": "A phase I study was conducted with oral irinotecan given daily for 14 days every 3 weeks in 45 patients with solid tumours to establish the maximum tolerated dose (MTD), toxicity, preliminary antitumour response and pharmacokinetics. Irinotecan was administered orally as a powder-filled capsule at doses ranging from 7.5 to 40 mg/m2 per day. Tumours were predominantly colorectal (30) together with 10 other gastrointestinal, 2 breast, 2 small cell lung and 1 ovarian. All but three patients had received prior chemotherapy. The median number of administered cycles was 3 (range 1-19). Gastrointestinal toxicities (grade 3 nausea, grade 3/4 vomiting and diarrhoea) and one incidence of grade 3 asthenia were dose limiting. There were no grade 3/4 haematological toxicities. The MTD was 30 mg/m2 per day. There were two documented partial responses, one in a patient with cancer of the small intestine and the other in a patient with colon cancer. Stable disease was seen in 16 patients (35.5%). Peak concentrations of irinotecan and metabolite SN-38 were reached within 2.0-2.4 h. The metabolic ratio of SN-38 AUC to irinotecan AUC was 0.17+/-0.10 (mean+/-SD). The dose recommended for phase II studies is 30 mg/m2 per day administered daily for 14 days every 3 weeks.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-004-0874-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "55"
      }
    ], 
    "name": "Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours", 
    "pagination": "263-270", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "25635b96667747f987e11b40440db26f38b99eced56e10b746c1c5cd20f94eec"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15592838"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-004-0874-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007848801"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-004-0874-2", 
      "https://app.dimensions.ai/details/publication/pub.1007848801"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000510.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-004-0874-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-004-0874-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-004-0874-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-004-0874-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-004-0874-2'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      21 PREDICATES      70 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-004-0874-2 schema:about N031df0fdd72b4a4ab6f013a39dca30c1
2 N334d6059103e46bf98e1b15b039f807c
3 N3563698127184802b949cf708516369e
4 N38393f69d04c47b6a843c42ce9987d1a
5 N3f58debac52a497b94f1721b0c935069
6 N4f32dbd219474c248dd8a154e7329fc3
7 N71a1b775cb4d482f9b6fd2834c331b77
8 N72e1d87cd52b4b3ca62670280f9cfbc2
9 N7ccca875444a49239a7769b245c4159e
10 N872b760ef7ec4548925e28f4ca9fe7c3
11 Nbb708a047ec1472383746ac02427b163
12 Nc28c8874e7e84adbb88d9a3222f3103d
13 Nd88a08baedb84314845cc7c536db216d
14 Necebb406afb3479b8028d7c12c7ee3e8
15 Nf865f8440bd54acb91c827efacf5a8dc
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N19cbf08c195140b0a3222b7db60de2c3
19 schema:citation sg:pub.10.1007/bf00686188
20 sg:pub.10.1038/bjc.1997.491
21 https://app.dimensions.ai/details/publication/pub.1074698413
22 https://app.dimensions.ai/details/publication/pub.1074859792
23 https://app.dimensions.ai/details/publication/pub.1083312377
24 https://app.dimensions.ai/details/publication/pub.1083347163
25 https://doi.org/10.1002/(sici)1097-0142(19990215)85:4<786::aid-cncr5>3.0.co;2-9
26 https://doi.org/10.1016/s0140-6736(00)02034-1
27 https://doi.org/10.1016/s0140-6736(98)02309-5
28 https://doi.org/10.1016/s0140-6736(98)03085-2
29 https://doi.org/10.1016/s0378-4347(98)00554-4
30 https://doi.org/10.1016/s0959-8049(98)00353-0
31 https://doi.org/10.1056/nejm200009283431302
32 https://doi.org/10.1056/nejm200107123450213
33 https://doi.org/10.1093/oxfordjournals.annonc.a059109
34 https://doi.org/10.1097/00001813-199704000-00002
35 https://doi.org/10.1200/jco.1996.14.3.709
36 https://doi.org/10.1200/jco.1997.15.1.110
37 https://doi.org/10.1200/jco.1997.15.1.251
38 https://doi.org/10.1200/jco.1997.15.4.1502
39 https://doi.org/10.1200/jco.1997.15.8.2910
40 https://doi.org/10.1200/jco.1999.17.2.685
41 https://doi.org/10.1200/jco.1999.17.6.1897
42 https://doi.org/10.1200/jco.2000.18.3.659
43 https://doi.org/10.1200/jco.2001.19.18.3801
44 https://doi.org/10.1200/jco.2001.19.5.1501
45 schema:datePublished 2005-03
46 schema:datePublishedReg 2005-03-01
47 schema:description A phase I study was conducted with oral irinotecan given daily for 14 days every 3 weeks in 45 patients with solid tumours to establish the maximum tolerated dose (MTD), toxicity, preliminary antitumour response and pharmacokinetics. Irinotecan was administered orally as a powder-filled capsule at doses ranging from 7.5 to 40 mg/m2 per day. Tumours were predominantly colorectal (30) together with 10 other gastrointestinal, 2 breast, 2 small cell lung and 1 ovarian. All but three patients had received prior chemotherapy. The median number of administered cycles was 3 (range 1-19). Gastrointestinal toxicities (grade 3 nausea, grade 3/4 vomiting and diarrhoea) and one incidence of grade 3 asthenia were dose limiting. There were no grade 3/4 haematological toxicities. The MTD was 30 mg/m2 per day. There were two documented partial responses, one in a patient with cancer of the small intestine and the other in a patient with colon cancer. Stable disease was seen in 16 patients (35.5%). Peak concentrations of irinotecan and metabolite SN-38 were reached within 2.0-2.4 h. The metabolic ratio of SN-38 AUC to irinotecan AUC was 0.17+/-0.10 (mean+/-SD). The dose recommended for phase II studies is 30 mg/m2 per day administered daily for 14 days every 3 weeks.
48 schema:genre research_article
49 schema:inLanguage en
50 schema:isAccessibleForFree false
51 schema:isPartOf N26c35ac8c1e24d75876fdb43728fee90
52 N53bd025b8a4c440d9f8621315027b874
53 sg:journal.1088364
54 schema:name Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours
55 schema:pagination 263-270
56 schema:productId N164b50d95c2243bb9162c6d20863ce8b
57 N5d422da40fd744c09679898a166fe73e
58 N724d07e4fd634348b3a2a86c89ba5b14
59 N9c6d8577bec84cb59e7971efc52f6d03
60 Nd8d8123f19f845739184b2d1c1d09ef7
61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007848801
62 https://doi.org/10.1007/s00280-004-0874-2
63 schema:sdDatePublished 2019-04-10T22:31
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher N4c4cbf8105494fafa64e1252dd8a9df3
66 schema:url http://link.springer.com/10.1007%2Fs00280-004-0874-2
67 sgo:license sg:explorer/license/
68 sgo:sdDataset articles
69 rdf:type schema:ScholarlyArticle
70 N019619a061b541ec9b4ed756742d6217 rdf:first sg:person.01324150036.10
71 rdf:rest N2fe10e7acf624d84a125c6d1b4e2cf02
72 N031df0fdd72b4a4ab6f013a39dca30c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Administration, Oral
74 rdf:type schema:DefinedTerm
75 N094adea85b9a4d9c8bd5c76668542f3c rdf:first sg:person.01351666475.99
76 rdf:rest N3b7be63699b14b00b6af78966c54fc9f
77 N164b50d95c2243bb9162c6d20863ce8b schema:name doi
78 schema:value 10.1007/s00280-004-0874-2
79 rdf:type schema:PropertyValue
80 N19cbf08c195140b0a3222b7db60de2c3 rdf:first sg:person.0660632545.22
81 rdf:rest N2482bdb01c0e430abfd36e3b29dfff6c
82 N2482bdb01c0e430abfd36e3b29dfff6c rdf:first sg:person.012165545074.60
83 rdf:rest N094adea85b9a4d9c8bd5c76668542f3c
84 N26c35ac8c1e24d75876fdb43728fee90 schema:volumeNumber 55
85 rdf:type schema:PublicationVolume
86 N26e251b1094048538672723ef6f26c80 rdf:first sg:person.013575273137.17
87 rdf:rest rdf:nil
88 N2c5b285de7b54f9690906101c599bc52 schema:name Aventis Pharma, 20, Avenue Raymond Aron, 92165, Antony cedex, France
89 rdf:type schema:Organization
90 N2fe10e7acf624d84a125c6d1b4e2cf02 rdf:first sg:person.01016732660.82
91 rdf:rest N26e251b1094048538672723ef6f26c80
92 N334d6059103e46bf98e1b15b039f807c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Middle Aged
94 rdf:type schema:DefinedTerm
95 N3563698127184802b949cf708516369e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Gastrointestinal Tract
97 rdf:type schema:DefinedTerm
98 N38393f69d04c47b6a843c42ce9987d1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Maximum Tolerated Dose
100 rdf:type schema:DefinedTerm
101 N3b7be63699b14b00b6af78966c54fc9f rdf:first sg:person.0710100376.50
102 rdf:rest Nb28dd7477c704385aadd1fec6a221697
103 N3f58debac52a497b94f1721b0c935069 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Camptothecin
105 rdf:type schema:DefinedTerm
106 N4c4cbf8105494fafa64e1252dd8a9df3 schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 N4f32dbd219474c248dd8a154e7329fc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Antineoplastic Agents, Phytogenic
110 rdf:type schema:DefinedTerm
111 N53bd025b8a4c440d9f8621315027b874 schema:issueNumber 3
112 rdf:type schema:PublicationIssue
113 N5d422da40fd744c09679898a166fe73e schema:name readcube_id
114 schema:value 25635b96667747f987e11b40440db26f38b99eced56e10b746c1c5cd20f94eec
115 rdf:type schema:PropertyValue
116 N71a1b775cb4d482f9b6fd2834c331b77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Neoplasms
118 rdf:type schema:DefinedTerm
119 N724d07e4fd634348b3a2a86c89ba5b14 schema:name pubmed_id
120 schema:value 15592838
121 rdf:type schema:PropertyValue
122 N72e1d87cd52b4b3ca62670280f9cfbc2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Male
124 rdf:type schema:DefinedTerm
125 N75e084f5bbf94ed1a3b7c2a88079713a schema:name Aventis Pharma, 20, Avenue Raymond Aron, 92165, Antony cedex, France
126 rdf:type schema:Organization
127 N7ccca875444a49239a7769b245c4159e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Drug Administration Schedule
129 rdf:type schema:DefinedTerm
130 N872b760ef7ec4548925e28f4ca9fe7c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 N9c6d8577bec84cb59e7971efc52f6d03 schema:name nlm_unique_id
134 schema:value 7806519
135 rdf:type schema:PropertyValue
136 Nb28dd7477c704385aadd1fec6a221697 rdf:first sg:person.01167077171.09
137 rdf:rest N019619a061b541ec9b4ed756742d6217
138 Nbb708a047ec1472383746ac02427b163 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Adult
140 rdf:type schema:DefinedTerm
141 Nc28c8874e7e84adbb88d9a3222f3103d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Aged
143 rdf:type schema:DefinedTerm
144 Nd88a08baedb84314845cc7c536db216d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Topoisomerase I Inhibitors
146 rdf:type schema:DefinedTerm
147 Nd8d8123f19f845739184b2d1c1d09ef7 schema:name dimensions_id
148 schema:value pub.1007848801
149 rdf:type schema:PropertyValue
150 Necebb406afb3479b8028d7c12c7ee3e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Female
152 rdf:type schema:DefinedTerm
153 Nf865f8440bd54acb91c827efacf5a8dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Enzyme Inhibitors
155 rdf:type schema:DefinedTerm
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
160 schema:name Oncology and Carcinogenesis
161 rdf:type schema:DefinedTerm
162 sg:journal.1088364 schema:issn 0344-5704
163 1432-0843
164 schema:name Cancer Chemotherapy and Pharmacology
165 rdf:type schema:Periodical
166 sg:person.01016732660.82 schema:affiliation https://www.grid.ac/institutes/grid.5477.1
167 schema:familyName Sanderink
168 schema:givenName Ger-Jan
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016732660.82
170 rdf:type schema:Person
171 sg:person.01167077171.09 schema:affiliation https://www.grid.ac/institutes/grid.5477.1
172 schema:familyName Beijnen
173 schema:givenName Jos H.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167077171.09
175 rdf:type schema:Person
176 sg:person.012165545074.60 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
177 schema:familyName Kuppens
178 schema:givenName I. E. L. M.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012165545074.60
180 rdf:type schema:Person
181 sg:person.01324150036.10 schema:affiliation N75e084f5bbf94ed1a3b7c2a88079713a
182 schema:familyName Assadourian
183 schema:givenName Sylvie
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324150036.10
185 rdf:type schema:Person
186 sg:person.01351666475.99 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
187 schema:familyName Huinink
188 schema:givenName Wim W. Ten Bokkel
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351666475.99
190 rdf:type schema:Person
191 sg:person.013575273137.17 schema:affiliation https://www.grid.ac/institutes/grid.5477.1
192 schema:familyName Schellens
193 schema:givenName Jan H. M.
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013575273137.17
195 rdf:type schema:Person
196 sg:person.0660632545.22 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
197 schema:familyName Schoemaker
198 schema:givenName Nadja E.
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660632545.22
200 rdf:type schema:Person
201 sg:person.0710100376.50 schema:affiliation N2c5b285de7b54f9690906101c599bc52
202 schema:familyName Lefebvre
203 schema:givenName Patricia
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710100376.50
205 rdf:type schema:Person
206 sg:pub.10.1007/bf00686188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043894508
207 https://doi.org/10.1007/bf00686188
208 rdf:type schema:CreativeWork
209 sg:pub.10.1038/bjc.1997.491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048065376
210 https://doi.org/10.1038/bjc.1997.491
211 rdf:type schema:CreativeWork
212 https://app.dimensions.ai/details/publication/pub.1074698413 schema:CreativeWork
213 https://app.dimensions.ai/details/publication/pub.1074859792 schema:CreativeWork
214 https://app.dimensions.ai/details/publication/pub.1083312377 schema:CreativeWork
215 https://app.dimensions.ai/details/publication/pub.1083347163 schema:CreativeWork
216 https://doi.org/10.1002/(sici)1097-0142(19990215)85:4<786::aid-cncr5>3.0.co;2-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027733495
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/s0140-6736(00)02034-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006410174
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/s0140-6736(98)02309-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017322568
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s0140-6736(98)03085-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034082860
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/s0378-4347(98)00554-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027875779
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1016/s0959-8049(98)00353-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037007269
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1056/nejm200009283431302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010303757
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1056/nejm200107123450213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036903462
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1093/oxfordjournals.annonc.a059109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082507233
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1097/00001813-199704000-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031175331
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1200/jco.1996.14.3.709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082882771
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1200/jco.1997.15.1.110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083031469
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.1997.15.1.251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083031490
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.1997.15.4.1502 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083105876
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.1997.15.8.2910 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083129507
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.1999.17.2.685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074265671
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.1999.17.6.1897 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549780
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2000.18.3.659 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074583472
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1200/jco.2001.19.18.3801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074881994
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1200/jco.2001.19.5.1501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074777260
255 rdf:type schema:CreativeWork
256 https://www.grid.ac/institutes/grid.430814.a schema:alternateName Antoni van Leeuwenhoek Hospital
257 schema:name Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
258 Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
259 rdf:type schema:Organization
260 https://www.grid.ac/institutes/grid.5477.1 schema:alternateName Utrecht University
261 schema:name Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
262 Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
263 Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, 3584 CA, Utrecht, The Netherlands
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...